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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: There is relatively little literature on prevalence of chronic kidney dis-
ease (CKD) prior to surgery in patients with upper urinary tract urothelial carcinoma (UTUC).
We evaluated the prevalence and clinical associated factors of baseline CKD in patients with
UTUC.
Methods: There were 785 patients with a pathologic diagnosis of UTUC from January 2002 to
December 2011 who were analyzed in this study. Estimated glomerular filtration rate (eGFR)
was calculated by re-expressed Modification of Diet in Renal Disease (MDRD) formulas for the
Chinese population. A multivariate logistic regression was performed to evaluate the odds ratios
(ORs) for CKD stage 3 or higher in UTUCs after data differences were tested.
Results: The prevalence of CKD in UTUCs presenting at our hospital was 58.6% and 70.8% in the
group age 70 years and older. Older age [per year increased; ORZ 1.050; 95% confidence interval
(CI): 1.034e1.067], lower tumor stage (T stage; per stage increased; ORZ 0.666; 95% CI: 0.544
e0.816), higher tumor grade (per grade increased; OR Z 1.392; 95% CI: 1.004e1.930) and
the main tumor locating in the pelvis (ureter as reference; ORZ 0.648; 95% CI: 0.475e0.885)
were independently associated with decreased kidney function in the multivariate logisticave no conflicts of interest relevant to this article.
t of Urology, Peking University First Hospital, Number 8, Xishiku Street, Xicheng District, Beijing
.com (X. Li), zhouliqunmail@sina.com (L. Zhou).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
3.04.001
522 G. Xiong et al.regression. The use of serum creatinine (Scr) only to evaluate the renal function would ignore a
large proportion of patients suffering fromCKD stage 3 inUTUCs, especially in those older than 70
years (39.3% vs. 54.1%, pZ 0.022).
Conclusion: We demonstrated a high prevalence (58.6%) of CKD in patients with UTUC, particu-
larly in the group older than 70 years (70.8%). Older age, lower T stage, higher tumor grade, and
the main tumor locating in pelvis (ureter as reference) were independently associated with CKD
in UTUCs.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Urothelial carcinoma is a malignant tumor differentiated
from the urothelial epithelium that could involve the
kidneys, ureters, bladder, and urethra. In upper urinary
tract carcinoma growing progress, the tumor would
become an obstacle in the urinary tract, and the ever-
increasing tract pressure could extend to all nephrons and
finally affect kidney function. Because of the high recur-
rence rate in the remaining ureter, nephroureterectomy
with bladder cuff excision is the standard treatment for
the upper urinary tract urothelial carcinomas (UTUCs).1,2
The patient’s renal function has become a particularly
important concern because there will be only one kidney
left after surgery. However, the extremely low prevalence
(according to statistical research, the urothelial carcinoma
occurs in the upper urinary tract in about 5% of all patients
with urothelial carcinoma)3 of UTUC limited the research
on revealing prevalence and factors associated with
baseline chronic kidney disease (CKD) in the population
with UTUC.
As CKD is being considered a serious worldwide public
health problem, increasing studies uncovered the adverse
relationship between long-term CKD and mortality.4e6 In
the UTUC area, one study has pointed out the positive
correlation between CKD and recurrence rate of the uro-
thelial carcinoma in the bladder.7 Another study found that
perioperative chemotherapy of this disease could have
been affected by the changes in renal function following
nephroureterectomy.8 According to the aforementioned
findings, renal function is a crucial factor if future
comprehensive therapeutic strategies are contemplated.
Compromised renal function may prevent appropriate
perioperative chemotherapy (cisplatin-based neoadjuvant
or adjuvant requires a glomerular filtration rate
(GFR)  60 mL/min, or at least 45 mL/min). Therefore, we
evaluated the baseline renal function of the patients with
UTUC and determined the prevalence of CKD in this cohort
of patients.
Recent data suggest that serum creatinine (Scr) is an
imperfect tool to estimate the degree of a patient’s renal
function.9 As defined by the American National Kidney
Foundation, the percentage of patients with a normal Scr
and a CKD stage 3 or greater is about 5%.10 To understand
how many patients with UTUC and CKD stage 3 or higher
had been ignored by using Scr as a single determinant of
renal function, we calculated estimated glomerular filtra-
tion rate (eGFR) for each patient and compared it with Scr.
Furthermore, we analyzed factors that might be associatedwith CKD, including age, sex, tumor size, tumor location,
tumor stage (T stage), lymph node status (N status), and
tumor grade.Materials and methods
The data source of this study (nZ 785; tumor recurrence or
complicating metastatic kidney disease were excluded
from the analysis) was all the patients who received
treatment in our center and in whom a pathologic diagnosis
of UTUC was made from January 2002 to December 2011.
After excluding distant metastasis, radical nephroureter-
ectomy, or distal ureterectomy (in patients with CKD stages
4 and 5 who had evidence of ipsilateral functional kidney,
or single-kidney patients) was performed in patients with
typical UTUC radiography, or with positive cytology with or
without fluorescence in situ hybridization assay. Uretero-
scopy with tumor biopsy was performed when radiography
was atypical to determine treatment strategy： Patients
with positive pathologic evidence received surgical treat-
ment and patients with negative evidence received reur-
eteroscopy or were closely followed up. All the pathologic
data analyzed in this study were identified from the
surgical specimens. eGFR was calculated using reexpressed
Modification of Diet in Renal Disease (MDRD) formulas
modified based on Chinese people: eGFR[mL/min/
1.73 m2]Z 175  Scre1.234  agee0.179  (0.79 if female).11
All the blood samples were collected prior to surgery (the
next morning of admission after forbidding food and water
for 8 hours) and sent to the central laboratory of Peking
University First Hospital where the reexpressed MDRD
equation was developed and detected under the same
methods. CKD stage was defined according to the criterion
provided by the American National Kidney Foundation.12
Statistical analysis
All the data were analyzed by SPSS version 18.0 software
(SPSS Inc., Chicago, IL, USA). After being stratified by Scr
and eGFR level, the data were presented as
mean  standard deviation (SD) for continuous variables
and exact number (with proportion) for categorical and
grade variables. Differences were analyzed by Student t
test for standard normally distributed continuous variables,
Mann-Whitney U test for nonstandard normally distributed
continuous variables and grade variables, and Chi-square
test for categorical variables. A multivariate logistic
regression was performed to evaluate the odds ratios (ORs)
Table 2 Chronic kidney disease stages in patients with
upper urinary tract urothelial carcinoma stratified by age
and normal serum creatinine.
Overall Patients with
normal Scr
(1.4 mg/dL)
Prevalence of CKD in UTUCs 523between eGFR  60 and eGFR < 60 under different expo-
sure variables, including age, sex, history of cardiovascular
disease, history of hypertension, history of diabetes, the
main tumor location, T stage, N status, tumor grade, single
or multiple, left/right/bilateral, maximum diameter, and
maximum short diameter. A p value less than 0.05 is
considered significant.CKD (all patients) 785 535
eGFR60 mL/min 325 (41.4) 325 (60.8)
Stage 3 (eGFR 30e59) 341 (43.4) 210 (39.3)
CKD (patients70 y) 346 220
eGFR60 mL/min 101 (29.2) 101 (45.9)
Stage 3 (eGFR 30e59) 195 (56.4) 119 (54.1)
Data presented as n (%) unless otherwise specified.
CKD Z chronic kidney disease; eGFR Z estimated glomerular
filtration rate; Scr Z serum creatinine.Results
Of the 785 patients who constituted the basis of this anal-
ysis, 44.6% were male. The mean age for this cohort was
66.3 (range, 20e94) years, and 759 patients (96.7%) were
older than 45 years.
Table 1 stratifies the patient group by baseline Scr and
baseline CKD stage. In all UTUC population, 535 patients
(68.2%) had a normal Scr using 1.4 mg/dL as the criteria.
On the contrary to Scr, the prevalence of baseline CKD
(stage 3 or higher) in the research population was 58.6%
(95% CI: 55.1e62.1%) as defined by the American National
Kidney Foundation by estimating patients’ eGFR using the
reexpressed MDRD formula modified on Chinese people: 341
patients (43.4%) had CKD stage 3, 54 patients (6.9%) had
CKD stage 4, and 65 patients (8.3%) had CKD stage 5.
Table 2 exposes the underestimation of patients with
CKD with a normal Scr in our UTUC population. There were
535 patients (68.2%) who had a normal Scr (1.4 mg/dL), of
which there were 210 patients (39.3%) with unrecognized
CKD stage 3 if the Scr was the single criteria for deter-
mining. There were 220 of 346 patients (63.6%) with a
normal Scr who were age 70 years or older, using the same
statistical methods; 119 patients (54.1%) with CKD stage 3
had been ignored in this older group. Even more significant,
in this cohort age 70 years or older the total percentage of
the patients with CKD stage 3 or higher (70.9%, the regular
group was 58.6%) or the ignored CKD stage 3 (54.1%, the
regular group was 39.3%) was more than half of the popu-
lation. In addition, in the patients with CKD stages 4 or 5,
all the Scr in the blood samples surpassed 1.4 mg/dL.
Table 3 presents mean  SD and for age, eGFR, Scr,
maximum diameter, maximum short diameter, and exact
number (with proportion) for sex, patients with history of
diabetes, patients with history of hypertension, patients
with history of cardiovascular disease, T stage, N status,Table 1 Patients stratified by serum creatinine and
chronic kidney disease stage.
n (%)
Scr (mg/dL)
1.4 535 (68.2)
1.5 250 (31.8)
CKD stage
eGFR60 325 (41.4)
Stage 3 (eGFR 30e59) 341 (43.4)
Stage 4 (eGFR 15e29) 54 (6.9)
Stage 5 (eGFR <15 or dialysis) 65 (8.3)
CKD Z chronic kidney disease; eGFR Z estimated glomerular
filtration rate; Scr Z serum creatinine.tumor grade, single/multiple, left/right/bilateral, and the
main tumor location of all patients with UTUC.
Table 4 lists ORs for eGFR less than 60 mL/min/1.73 m2
of all UTUC population. Older age (per year increased;
ORZ 1.050; 95% CI: 1.034e1.067), lower T stage (per stage
increased; ORZ 0.666; 95% CI: 0.544e0.816), higher tumor
grade (per grade increased; OR Z 1.392; 95% CI:
1.004e1.930) and the main tumor locating in the pelvis
(ureter as reference; OR Z 0.648 95% CI: 0.475e0.885)
were independently associated with decreased kidney
function in this multivariate logistic regression.
Discussion
As any classic physiology textbook describes, the kidney
undertakes the major excretion task of every organism by
synthesizing and excreting metabolic waste in the form of
urine. In such a process, the ultrafiltrate formation is
crucial. To evaluate the formation velocity of it, the defi-
nition of GFR has been defined and finally considered the
best overall index of kidney function. In clinical practice,
the MDRD equation has gained widespread acceptance and
has been applied generally in measuring renal function.13
The Chinese eGFR Investigation Collaboration has modi-
fied and verified this equation in 2006 because the deriva-
tion of the original MDRD equation was on the basis of the
Western populationdsupplying us the efficiency tool to
evaluate eGFR using our present data of Chinese patients
with UTUC.11
CKD is common. According to a recent cross-sectional
survey, the prevalence of CKD in adults in China was 10.8%
(95% CI, 10.2e11.3%).14 CKD contributes to increased risks
of death, cardiovascular events, probability of hospitali-
zation, and end-stage renal disease with the decrease in
eGFR.6 For most of the patients with UTUC, there will be
only one kidney left after surgery and it has been certified
that radical nephrectomy has a negative effect on kidney
function and the eGFR in the patients with renal cortical
tumors.15 Excluding the direct tumor association factors
such as tumor recurrence, the CKD stage should be another
crucial factor affecting survival in this cohort of patients.
According to one study, the risk of death increased as the
Table 3 Characteristics of the upper urinary tract urothelial carcinoma population (univariate analysis).
Total (n Z 785) eGFR60 mL/min eGFR<60 mL/min p
Age 66.63  0.38 63.46  0.63 68.88  0.44 <0.001
Male 350 (45) 156 (45) 194 (55) 0.1
Female 435 (55) 169 (39) 266 (61)
Scr (mg/dL) 1.74  0.06 0.99  0.01 2.27  0.09 <0.001
Maximum diameter (cm) 3.41  0.08 3.65  0.15 3.25  0.10 0.4
Maximum short diameter (cm) 1.33  0.04 1.38  0.06 1.30  0.05 0.4
History of diabetes 131 (17) 45 (34) 86 (66) 0.1
History of HT 315 (40) 110 (35) 205 (65) 0.003
History of CVD 98 (12) 31 (32) 67 (68) 0.03
Tumor characteristics
Single 657 (84) 277 (42) 380 (58) 0.3
Multiple 128 (16) 48 (38) 80 (63)
Left 392 (50) 159 (41) 233 (59) 0.6a
Right 391 (50) 166 (42) 225 (58)
Bilateral 2 (0.25) 0 (0) 2 (1)
Main tumor location
Pelvis 414 (53) 164 (40) 250 (60) 0.3
Ureter 371 (47) 161 (43) 210 (57)
Tumor stage
T1 (including Ta) 275 (35) 96 (35) 179 (65) 0.007
T2 273 (35) 111 (41) 162 (59)
T3 216 (28) 106 (49) 110 (51)
T4 21 (3) 12 (57) 9 (43)
N status
N0 732 (93) 295 (40) 437 (60) 0.02
Nþ 53 (7) 30 (57) 23 (43)
Tumor grade
G1 16 (2) 7 (44) 9 (56) 0.9
G2 430 (55) 178 (41) 252 (59)
G3 339 (43) 140 (42) 199 (59)
Data presented as n (%) unless otherwise specified.
CVD Z cardiovascular disease; HT Z hypertension.
a Ignored the effect of bilateral patients.
524 G. Xiong et al.GFR decreased below 60 mL/min in the San Francisco Bay
area, the hazard ratio for death was 1.2 with an estimated
GFR of 45e59 mL/min, 1.8 with an estimated GFR of
30e44 mL/min, 3.2 with an estimated GFR of 15e29 mL/
min, and 5.9 with an estimated GFR of <15 mL/min.6 In
other words, in regard to patient renal function it could be
beneficial to predict patient survival. Considering the
standard surgical procedure (nephroureterectomy with
bladder cuff excision) of patients with UTUC, surgeons
should pay more attention to the CKD.
In our retrospective study, the prevalence of baseline
CKD (stage 3 or higher) in the research population was
58.6% of all 785 patients with UTUC and 70.8% in the group
age 70 years or older. The prevalence was much higher
compared with the normal person and even the patients
with renal tumor. Considering the prevalence of CKD
increased with age, and in our study, 759 patients (96.7%)
were older than 45 years, we compared three sets of data
to certify authenticity of this conclusion. In the National
Health and Nutrition Examination Survey (NHANES) in
1999e2004, the cohort of individuals with CKD was less than
9% (9% vs. 58.6%, p < 0.001), even in the group age 70 years
or older, the CKD stage 3 or higher was less than 40% of allpopulation (40% vs. 70.8%, p < 0.001).10 In a CKD study of
patients in Beijing, the prevalence was 13.0 % (13.0% vs.
58.6%, p < 0.001) and 30.5 % (30.5% vs. 70.8%, p < 0.001) in
the population age 70 years or older.16 In another study of
CKD prevalence in patients presenting with solid renal tu-
mors, the total proportion was 22% (22% vs. 58.6%,
p < 0.001) and in the group age 70 years or older it was 40%
(40% vs. 70.8%, p < 0.001).17 In the physiology viewpoint,
the velocity of the ultrafiltrate formation is decided by the
character of filtrate membrane and effective filtration
pressure, which would be greatly influenced by glomerular
plasma flow rate and renal capsule pressure. Compared
with renal tumor, the urothelial carcinoma differentiated
from the urothelium would become an obstacle in the uri-
nary tract in its growing progress. In this situation, the renal
capsule pressure of all nephrons could be affected, and
finally contribute to lower filtration and higher stage of
CKD. Alternately, the renal tumors could just oppress part
of the kidney and affect the GFR of this definite area.
Attributed to the powerful reserve of renal function, the
left normal nephron could compensatory work well and may
finally cover the influence of GFR, which may explain the
aforementioned phenomena. Still, in this study, the
Table 4 Odds ratios for estimated glomerular filtration
rate less than 60 mL/min/1.73 m2 of all patients with upper
urinary tract urothelial carcinoma.
Input variables (n Z 785) OR 95% CI p
Sex (male as reference) 1.085 0.800e1.472 0.6
Age (per yr increased) 1.051 1.034e1.067 <0.001
Maximum diameter 0.957 0.895e1.023 0.2
Maximum short diameter 1.104 0.915e1.332 0.3
History of diabetes 1.186 0.782e1.799 0.4
History of hypertension 1.311 0.960e1.791 0.09
History of cardiovascular
disease
1.079 0.663e1.757 0.8
Tumor stage (per stage
increased)
0.689 0.560e0.847 <0.001
N status (N0 as reference
vs. Nþ)
0.573 0.309e1.063 0.07
Tumor grade (per grade
increased)
1.392 1.004e1.930 0.047
Location (pelvis as reference
vs. ureter)
0.631 0.461e0.864 0.004
Location (Left as reference
vs. right)
0.972 0.722e1.309 0.9
Single vs. multiple (single as
reference)
1.266 0.837e1.913 0.3
CI Z confidence interval; eGFR Z estimated glomerular filtra-
tion rate; N status Z lymph node status; OR Z odds ratio.
Prevalence of CKD in UTUCs 525percentage of patients with CKD stages 4 and 5 and renal
tumor was just 2%; however, this proportion increased
significantly to 15.2% (95% CI: 12.8e17.9%) in our patients
with UTUC (p < 0.01). Through telephone follow-up, we
ascertained another explanation for this interesting phe-
nomenon excluding the reason mentioned earlier: in China,
without systematic and standardized physical examination
of all citizens, some patients’ disease was noticed late,
when some apparent symptoms had appeared. Even though
CKD had been diagnosed in some, they could not receive
blood dialysis until their Scr surpassed 707 mmol/L (8 mg/
dL) to meet the minimum requirements for medical
insurance.
In our study, there were 210 of 535 patients (39.3%) with
unrecognized CKD stage 3 if the Scr 1.4 mg/dL is the single
criteria, and in the group age 70 years or older, the propor-
tion was much more significantd119 of 220 (54.1%)
(pZ 0.022), and this phenomena might affect the compre-
hensive treatment of UTUCs. The role of neoadjuvant and
adjuvant chemotherapy has been extensively studied in the
bladder urothelial carcinoma. Grossman et al18 reported an
increase in 5-year disease-free survival of 14% in the cohort
receiving neoadjuvant chemotherapy containing cisplatin
in combination with radical cystectomy.18 Because UTUCs
are urothelial tumors, cisplatin-based chemotherapy is ex-
pected to produce results similar to those with bladder tu-
mors. In recent studies, some chemotherapy regimens have
been proposed,19e21 and have even supported the efficacy of
cisplatin-based neoadjuvant therapy in lower tract urothe-
lial carcinoma.18,22 However, cisplatin-based neoadjuvant or
adjuvant requires patients’ GFR  60 mL/min (at least45mL/min) to excrete the poisonousmetabolic waste. Thus,
with the development of comprehensive treatment for
tumors, the clinicians should pay more attention to their
patients’ renal function and reconsider the treatment stra-
tegies when the evidence of neoadjuvant chemotherapy
would be certified in the future. Because with the resection
of the tumor, ipsilateral urinary tract, and kidney, the ever-
decreasing renal function could destroy the opportunity to
receive perioperative chemotherapy and may enhance the
risk of death for patients with UTUC.
Analyzing the ORs obtained from the multivariate logistic
regression for eGRF < 60 mL/min/1.73 m2 in the UTUC
population, we evaluated four statistically significant clin-
ical factors associated with decreasing kidney function:
older age, lower T stage, higher tumor grade, and the main
tumor locating in the pelvis versus the ureter. Older age has
been reported to be an independent risk factor related to
CKD,12,16 supported further by the current study. In one
retrospective study of characteristics of UTUC in Balkan
patients with endemic nephropathy patients, lower tumor
stage (pTa-pT1) predominated in UTUCs from the endemic
and adjacent but not the control settlements in the period
1957e1986 and higher grade predominated in endemic set-
tlements from 1987e2006.23 This phenomenon predicted
UTUCs caused by aristolochic acid might have lower tumor
stages and higher tumor grade. Considering the nationwide
use of traditional Chinese medicine (TCM) in China, some
tumors in patients with UTUC might be detected late after
their renal function had been damaged by some kind of TCM
containing aristolochic acid. Despite the lack of detailed
medication history record, there was onemore phenomenon
contrary to theWestern countries UTUCs but the same as the
Balkans supporting this hypothesis23,24: the prevalence of
UTUC in our center was lower in Chinese men compared with
Chinese women (44.6% vs. 55.4%, p Z 0.013). This may
partly explain the relationship between T stage and CKD in
patients with UTUC of our hospital.
This study has certain limits and constraints. It was a
retrospective study and all the eGFRs were evaluated based
on a single reexpressed MDRD formula. Though this study
had a large sample size, the single measurements might
lead to an inaccurate prevalence of CKD. However, this
reexpressed MDRD formula has gained widespread accep-
tance in China and has been applied in some large sample
studies for the Chinese population.14,16 It is reasonable to
believe the equation and its deviation to eGFR would be
more perspicuous in the future. Still, in this study, we
determined the main tumor locating in the pelvis (ureter as
reference) was associated with CKD in UTUCs, but failed to
find any theory to explain this phenomena. Additional
investigation is required to study the role of CKD in tumor
recurrence and mortality.
In conclusion, we demonstrated a high prevalence
(58.6%) of CKD in patients with UTUC attending Peking
University First Hospital from 2002 to 2011, particularly in
the cohort age 70 years or older (70.8%). In the Scr normal
group, approximately 40% of patients had unrecognized
CKD stage 3, the proportion was much greater in the cohort
age 70 years or olderd54.1%. Older age, lower T stage,
higher tumor grade, and the main tumor locating in pelvis
(ureter as reference) were significant clinical factors asso-
ciated with CKD in UTUCs.
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